ClearPoint Neuro (CLPT) AI Stock Analysis

• Market Cap: $458.42M
• Dividend Yield: N/A
• Average Volume (3M): 672.96K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.58
• Revenue Growth: 12.83%
• EPS Growth: -19.53%
• Country: US
• Employees: 115
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.21
• Shares Outstanding: 29,748,308
• 10 Day Avg. Volume: 676,791
• 30 Day Avg. Volume: 672,960
• PEG Ratio: 0.99
• Price to Book (P/B): 16.37
• Price to Sales (P/S): 13.24
• P/FCF Ratio: -45.06
• Enterprise Value/Market Cap: 1.35
• Enterprise Value/Revenue: 17.97
• Enterprise Value/Gross Profit: 29.31
• Enterprise Value/Ebitda: -28.91
• 1Y Price Target: $29.00
• Price Target Upside: 6.15% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -0.8
• Revenue Forecast (FY): $50.60M

• Rating: 51 Neutral
• Price Target: $14.00 ▼(-48.76% Downside)

The score is held back primarily by weak financial performance (large losses, negative ROE, and ongoing cash burn) despite strong top-line growth and solid gross margins. Technical signals are mixed with negative MACD and price below longer-term moving averages, while valuation is difficult to support given negative earnings. The earnings call adds a positive offset due to clearer strategy, improving gross margin, and expected scale benefits from the IRRAS combination.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective sales strategies, supporting long-term business expansion.

Strategic Merger

The merger with IRRAS expands ClearPoint's market reach and product portfolio, strengthening its competitive position in neurocritical care.

Strong Balance Sheet

A strong balance sheet with low leverage enhances financial stability, providing flexibility for future investments and growth.

Negative Factors

Negative Profit Margin

Sustained negative profit margins highlight ongoing operational challenges, which could hinder long-term profitability and cash flow.

Increased Operating Expenses

Rising operating expenses can pressure margins and limit the ability to achieve profitability, affecting financial health over time.

Negative Operating Cash Flow

Negative operating cash flow suggests reliance on external funding, which may not be sustainable and could limit future growth opportunities.

ClearPoint Neuro Business Overview & Revenue Model

Company Description

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

How the Company Makes Money

ClearPoint Neuro generates revenue primarily through the sale of its medical devices and systems used in neurosurgery. This includes the ClearPoint System and related components, which are sold to hospitals and surgical centers. The company also earns revenue from software services and maintenance agreements associated with its products. Additionally, ClearPoint Neuro has established partnerships with pharmaceutical and biotech companies to support clinical trials and research, which can provide additional revenue streams through collaborative agreements and licensing fees. The growth of its revenues is supported by increasing demand for innovative neurosurgical solutions and advancements in brain disease treatment.

ClearPoint Neuro Financial Statement Overview

Summary

ClearPoint Neuro shows strong revenue growth and a solid balance sheet with low leverage. However, the company struggles with profitability and negative operating cash flow, which are critical for long-term sustainability.

Income Statement

ClearPoint Neuro has shown a consistent increase in revenue over the years, with a notable revenue growth rate of 31% from 2023 to 2024. However, the company continues to operate at a loss with a negative net profit margin of -60.3% in 2024. The gross profit margin remains strong at 60.9%, indicating efficient cost management relative to revenue. The EBIT and EBITDA margins remain negative, reflecting ongoing operational challenges.

Balance Sheet

The company's balance sheet shows improvement in stockholders' equity, which increased to $25.4 million in 2024 from $21.2 million in 2023. The debt-to-equity ratio has improved significantly over the years, standing at 0.14 in 2024, indicating lower leverage risk. The equity ratio is robust at 64.8%, highlighting a strong capital structure. However, the company needs to address its negative net income for better return on equity.

Cash Flow

ClearPoint Neuro's cash flow situation shows a positive trend in free cash flow growth, with free cash flow improving by 37.6% from 2023 to 2024. However, the operating cash flow remains negative, which could impact long-term sustainability. The company has been financing its operations through external funding, as seen in its financing cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	34.33M	31.39M	23.95M	20.55M	16.30M	12.83M
Gross Profit	21.05M	19.12M	13.61M	13.53M	11.12M	9.12M
EBITDA	-21.34M	-17.84M	-20.99M	-15.58M	-12.74M	-4.79M
Net Income	-23.14M	-18.91M	-22.09M	-16.43M	-14.41M	-6.78M
Balance Sheet
Total Assets	60.36M	39.19M	42.66M	55.49M	65.58M	29.52M
Cash, Cash Equivalents and Short-Term Investments	38.22M	20.10M	23.14M	37.49M	54.11M	20.10M
Total Debt	35.74M	3.57M	13.94M	11.99M	12.28M	24.12M
Total Liabilities	44.48M	13.80M	21.49M	18.60M	16.79M	27.14M
Stockholders Equity	15.87M	25.39M	21.17M	36.89M	48.79M	2.38M
Cash Flow
Free Cash Flow	-13.82M	-9.22M	-14.44M	-16.42M	-12.87M	-8.29M
Operating Cash Flow	-13.09M	-8.95M	-13.72M	-16.17M	-12.70M	-7.81M
Investing Cash Flow	-736.00K	-275.00K	8.95M	-10.74M	-168.00K	-482.00K
Financing Cash Flow	30.65M	6.19M	296.00K	409.00K	46.88M	22.69M

ClearPoint Neuro Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 27.32
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLPT, the sentiment is Neutral. The current price of 27.32 is above the 20-day moving average (MA) of 14.45, above the 50-day MA of 14.55, and above the 200-day MA of 14.35, indicating a bullish trend. The MACD of 0.09 indicates Negative momentum. The RSI at 49.71 is Neutral, neither overbought nor oversold. The STOCH value of 41.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CLPT.

ClearPoint Neuro Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BVS	64 Neutral	$640.59M	71.15	4.97%	―	1.58%	―
AVNS	59 Neutral	$550.99M	-1.21	-46.68%	―	2.70%	-3090.51%
SIBN	57 Neutral	$756.74M	-34.40	-12.91%	―	23.27%	43.90%
OFIX	55 Neutral	$567.07M	-4.74	-24.60%	―	4.31%	3.26%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CLPT	51 Neutral	$458.42M	-17.73	-103.13%	―	12.83%	-19.53%

ClearPoint Neuro Corporate Events

ClearPoint Neuro Restructures IRRAS Subsidiary Under Debt Agreement

On December 29, 2025, ClearPoint Neuro entered into a consent agreement with CALW SA LLC and TPC Investments III LP, an affiliate of Oberland Capital Management, related to an existing Note Purchase Agreement originally executed in May 2025 and amended in November 2025. Under the consent, ClearPoint Neuro agreed to complete by January 15, 2026 an internal reorganization of its Swedish subsidiary IRRAS AB, including transferring all equity interests in IRRAS USA, Inc. from IRRAS AB to ClearPoint or its direct U.S. subsidiary in exchange for a subordinated intercompany note, and to take additional steps so that IRRAS AB qualifies as an “Immaterial Foreign Subsidiary” under the Note Purchase Agreement. The consent preserves the material economic terms of the company’s financing arrangements while restructuring ownership of the IRRAS assets, which may streamline the company’s capital structure and compliance with its debt covenants following the IRRAS acquisition.

The most recent analyst rating on (CLPT) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on ClearPoint Neuro stock, see the CLPT Stock Forecast page.

ClearPoint Neuro Completes Acquisition of IRRAS Holdings

On November 20, 2025, ClearPoint Neuro completed its acquisition of IRRAS Holdings, Inc., enhancing its commercial scale and supporting its long-term strategy in CNS drug delivery innovation. The acquisition, valued at $5.0 million in cash and 1,325,000 shares of common stock, brings the novel IRRAflow system into ClearPoint’s portfolio, expanding its presence in neurocritical care and complementing its existing technologies. This strategic move is expected to drive operational leverage and meaningful value for stakeholders by combining IRRAS’s differentiated technology with ClearPoint’s existing ecosystem.

The most recent analyst rating on (CLPT) stock is a Hold with a $18.50 price target. To see the full list of analyst forecasts on ClearPoint Neuro stock, see the CLPT Stock Forecast page.

ClearPoint Neuro Announces Merger with IRRAS Holdings

On November 6, 2025, ClearPoint Neuro announced a merger agreement with IRRAS Holdings, Inc., a medical technology company specializing in neurocritical care. This strategic acquisition is expected to expand ClearPoint Neuro’s drug delivery portfolio and add commercial scale across a $0.5 billion market for intracranial bleeding treatment. The merger will provide ClearPoint Neuro access to a large existing market and enhance its operational scale with an expanded commercial team. The combined entity is projected to achieve significant revenue growth, with an estimated total revenue range of $54.0 to $60.0 million for 2026.

The most recent analyst rating on (CLPT) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on ClearPoint Neuro stock, see the CLPT Stock Forecast page.

ClearPoint Neuro Reports Q3 Results and Strategic Advances

On November 6, 2025, ClearPoint Neuro reported its third-quarter financial results, highlighting a 9% year-over-year revenue increase to $8.9 million and reaffirming its full-year forecast. The company announced several strategic advancements, including the operational launch of its new pre-clinical CRO facility, FDA clearance for expanded use of its PRISM Laser Therapy System, and a prototype Robotic Neuro-Navigation System. Additionally, ClearPoint Neuro is expanding its international regulatory approvals and has signed an agreement to acquire IRRAS Holdings, Inc., which will broaden its market reach into neurocritical care. These developments are expected to enhance the company’s market position and support its growth strategy across four pillars, including biologics and drug delivery, neurosurgery navigation, laser therapy, and the newly introduced cranial irrigation and aspiration.

The most recent analyst rating on (CLPT) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on ClearPoint Neuro stock, see the CLPT Stock Forecast page.